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The diagnosis of recurrent syncope in patients with pacemakers (PM) is quite challenging
and the etiology of syncope is often multifactorial. To portray the mechanism of syncope in
PM patients, we report the results of head-up tilt table testing (HUT) in a series of patients
with PM, originally implanted for reasons other than neurally mediated syncope, referred
due to syncope or pre-syncope (aborted syncope, vertigo, suspected orthostatic
hypotension).
Forty-one patients with PM undergoing a HUT in our syncope unit between January 1st,
2007 and December 31st 2011 were included. A standard HUT protocol with nitroglycerine
provocation was used and the test results were classified according to current guidelines.
Baseline data were retrieved from the medical records.
Overall, 54% of patients had a positive response to HUT. Vasodepressor or orthostatic hy-
potensive response were the most prevalent responses accounting for 72% of patients with
a positive test. There were no differences between groups with positive or negative test
result regarding age, gender, resting blood pressure and heart rate, daily fluid intake,
pacing mode, pacing indication or pacing rhythm at rest.
HUT in patients with pacemakers has a high diagnostic yield. Although, the majority of
patients had a vasodepressor or orthostatic hypotensive response, cardioinhibitory
response leading to syncope was also seen.
Copyright © 2015, Indian Heart Rhythm Society. Production and hosting by Elsevier B.V.
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Reflex syncope, also known as neurally-mediated syncope or
neurocardiogenic syncope is prevalent with a mixed reaction
of vasodilatation and bradycardia (vasovagal syncope) being
the most common response [1,2]. Even though the cause of
reflex syncope is benign, recurring syncope can have profound
impact on the quality of life comparable to chronic illnesses
such as rheumatoid arthritis [1,3]. Diagnosing reflex syncope
can be challenging and patients often undergo multiple
diagnostic tests (i.e., echocardiography, Holter monitoring, CT
scans etc). HUT is suggested for the evaluation of suspected
reflex syncope both in patients with and without structural
heart disease [4]. In trials focusing on pacemaker (PM) treat-
ment for neurocardiogenic syncope, the recurrence rate for
syncope in patients with PM varies quite considerably (0e78%)
depending on mode of pacing and population investigated
[5e11] illustrating that PM treatment does not exclude the
presence of reflex syncope. However, little information is
available concerning these patients with “break-through”
episodese especially concerning the type and mode of
syncope.
The aim of our study was thus, to further illustrate the
relation between recurrent syncope and pacemaker therapy
and its mechanisms. We wanted to describe the outcome of
head-up tilt table test (HUT) in patients with pacemakers
implanted for a variety of conditions and referred with syn-
cope or pre-syncope to our syncope unit.Methods
Forty-one patients with PM undergoing a HUT in our syncope
unit between January 1st, 2007 and December 31st, 2011 were
included. No patients were excluded due to technical issues or
lack of data. A standard protocol was used with an initial
10 min of supine rest and then 20 min head-up tilt to 60
[1,12,13]. If only limited changes in heart rate (HR) or blood
pressure (BP) had occurred, nitroglycerine 400 mg was admin-
istered sublingually and patients remained tilted for up to
15 min. After discontinuation of tilting patients were moni-
tored for a minimum of 5 min in the supine position. HR and
BP were continuously measured using standard 3-lead ECG
and finger photoplethysmography (Finometer, Finapres Med-
ical Systems B.V., TheNetherlands) respectively. The accuracy
of finger-BP was assured by continuously comparing to stan-
dard arm BP, not allowing for more than 25 mmHg divergence
[13]. HR and BP together with temporal markers for tilt start,
nitroglycerine dosing and tilt stop were recorded digitally by
commercial software (Chart 5.59 with HRV module, AD In-
struments Inc, Colorado Springs, CO, USA). Tilting was dis-
continued if syncope or severe symptoms occurred coinciding
with significant HR or BP changes or with completion of the
protocol in the absence of symptoms. The test was supervised
by an experienced nurse with a physician immediately
available if needed. Tests were classified according to the
current guidelines [1,13,14]. In order for a test to be designated
positive, HR and/or BP changes had to occur simultaneously
with symptoms,which the patient could associatewith earlierexperienced syncope/pre-syncope episodes [1,13]. Patients
were divided in two groups according to tilt table outcome,
one group with any type of positive HUT and the other group
with negative (normal) HUT. Data were retrieved from the
department's digitized medical records. All patients had
normal functioning PM, with normal checks and pacemaker
readout before and after tilt table testing. The distribution of
PM types were as follows 18 with DDD-R pacemakers (one of
which was an ICD), 10 with ICD-VVI-R pacemakers, 9 with
VVI-R pacemakers, 3 with AAI-R pacemakers and one with
VDD pacemaker. Indications for PM implantations were as
seen in Fig. 1, and no patients had PM implanted specifically
due to neurocardiogenic syncope.Statistics
Descriptive statistics are presented as mean and SD, cate-
gorical data are presented in percentage. In tables with com-
parisons mean and SEM are used. Patients were allocated into
two groups according to tilt table test outcome (positive/
negative). A student t-test was used to test for difference be-
tween the groups for numerical data and tested with chi2-test
for categorical data. In case of less than 5 expected values in
any column, Fisher's exact test was computed. A two-sided P
value less than 0.05 was considered significant. All statistics
were done in SAS 9.1.3 (SAS Institute Inc, Cary, NC).Results
A total of 41 patients were included with a mean age 64 ± 17
years (range 16e85 years) and 66% were men (Table 1).
Symptoms that lead to referral for tilt table testing
included syncope in 61% and pre-syncope including vertigo or
suspected orthostatic hypotension in 39%. Indications for PM
implantation in the included population are shown in Fig. 1,
with themajority of patients having received pacemakers due
to AV-block, SA-block, or sinus node dysfunction. Patients
with ventricular tachycardia or cardiomyopathy all had
received an ICD (ICD_V, single ICD_D). None of the patients
had received PM specifically for neurocardiogenic syncope.
Two patients had prophylactic ICD pacemakers due to
ischemic heart disease and left ventricular dysfunction. Three
patients with other indications all had DDD-pacemakers due
to bundle branch block (triphasic/right) and one due to sus-
pected sinus caroticus syndrome.
The outcome of tilt table testing is shown in Fig. 2. Overall,
54% of patients had a positive response. Vasodepressor or
orthostatic hypotensive response was the most prevalent ac-
counting for 39% of all patients and 72% of patients with
positive test.
In 6 patients that predominately had sinus rhythm, a car-
dioinhibitory or mixed response was seen with activation of
pacing that could not prevent syncope or significant BP/HR
drops. The pacemakers were activated due to bradycardia
associated with BP drop in 3 patients with mixed response,
one patient had second degree AV-block in association
with BP drop (mixed response), one patient developed third
degree AV-block and one patient had 15 s asystole (no
Fig. 1 e Indications for pacemaker therapy in the included population.
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pacing in AAI- Fig. 3).
Of the nine patients who were paced throughout the test 5
had a normal test, 3 patients had orthostatism and one had
vasodepressor response. Of the four patients who had inter-
mittent but predominately paced rhythm, 2 had a normal test
and 2 had vasodepressor response.
Among the patients that predominately had sinus rhythm,
11 patients had a normal test with no or very limited pace-
maker activity and eight patients had vasodepressor re-
sponses with no bradycardia and no pacemaker activity in
relation to BP drop. Most of these patients had compensating
increase in HR as the BP dropped.
There were no significant differences between the results
of HUT with respect to pacing mode (Fisher's exact test
p ¼ 0.28, Table 1), although all patients with atrial pacing
systems had a positive test (n ¼ 3). In two patients, a car-
dioinhibitory response was seen despite functioning pacing
systems, one with 2:1 AV-block with heart rate <40 bpm
(pacing starts after 5 s) and one with “functional” total AV-
block with no atrioventricular conduction of atrial pacing
(Fig. 3).
There were no differences between the groups with posi-
tive tests and negative tests regarding age, gender, baseline
values, daily fluid intake or pacing rhythm at rest (Table 1).Table 1 e Baseline data for whole population and population s
Total
N ¼ 41
Mean ± SD
Age (years) 64 ± 17
Gender (% male) 66%
Resting
Systolic BP (mmHg) 123 ± 25
Diastolic BP (mmHg) 73 ± 18
Heart Rate (bpm) 71 ± 10
Left Ventricular ejection fraction (%) 49 ± 6
Daily fluid intake (l/day) 2.0 ± 0.8
Paced rhythm at rest 37%
Pacing Modality
Atrial (No.) 3
Ventricular (No.) 20
Dual (No.) 18Patients who had PM implanted due to AV-block, sinus node
dysfunction/SA-block or all other indications as a group did
not differ in outcome of HUT (p ¼ 0.18, Fisher's exact test).
Symptoms and/or syncope occurred after 21 min (range
1e27 min), with the majority seen after nitroglycerine provo-
cation (90%). In all positive tests, the BP started to drop before
any decrease in HR was seen. In the group with positive tests,
the PM was constantly active during the whole test in 6 pa-
tients, the PM was activated at syncope (but not preventing
positive outcome) in 7 patients and no PM activity was
apparent in 9 patients.Discussion
The main finding in our study was that HUT in patients with
implanted pacemakers referred for postural symptoms or
possible syncope had a high diagnostic yield. We found that
the response to HUT was primarily one of vasodilatation or
postural hypotension. Some patients showed significant re-
ductions in heart rate despite normal functioning pacemaker.
Thus, HUT provided valuable clinical information in pace-
maker patients and could lead to revised device- or medical
management.tratified according to tilt table.
Tilt test outcome
Positive Negative p-value
N ¼ 22 N ¼ 19
Mean ± SEM Mean ± SEM
62 ± 3.9 65 ± 3.8 P¼ 0.58
59% 74% P¼ 0.33
126 ± 5.3 120 ± 5.7 P¼ 0.42
75 ± 3.8 71 ± 4.2 P¼ 0.45
69 ± 2.1 72 ± 2.2 P¼ 0.36
51 ± 5 47 ± 7 P¼ 0.06
2.1 ± 0.2 1.8 ± 0.2 P¼ 0.30
31% 42% P¼ 0.50
P¼ 0.28
3 0
9 11
10 8
Fig. 2 e Tilt table outcomes according to current guidelines.
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implantation of VVI pacemakers by Pavlovic et al. [15], a
thorough work up including HUT could identify a cause of
syncope in 70% of patients, primarily due to abnormal HUT.
In their series, 63% of patients had a negative HUT,
compared to 46% in our study e a difference that could be
attributed to differences in protocols (passive vs. nitroglyc-
erine) as addition of nitroglycerine provocation increases
the diagnostic yield and the test sensitivity [16]. Vaso-
depressor reaction with hypotension leading to syncope was
seen in 34%, directly comparable to our result of 32%. At one
year follow-up, Pavlovic et al. observed that most patients
continued to experience syncope, except one patient where
the PM was replaced due to exit block. Only rarely was PM
dysfunction the underlying cause of syncope (6%) [15].
Similar results were seen in patients with sick sinus node
syndrome. In 70% of cases, recurrent syncope could be
explained by vasovagal responses (18%), orthostatic hypo-
tension (26%), arrhythmias (17%), ischemia (3%) or pace-
maker dysfunction (7%) [17]. Keim et al. [18] reported a
series of eight patients with pacemaker and recurrentFig. 3 e Sixty-four year old male who had an AAI-pacing system
node dysfunction with bradycardia. Continuously ECG and bloo
asystole with atrial pacing artefact/atrial activation without atr
and syncope. There was spontaneous restoration of atrioventrisyncope. In all patients, the tilt test was positive with 50%
pure vasodepressor, 38% mixed and 12% cardioinhibitory
responses, thus with a distribution of positive tests being
somewhat similar to our results.
Cardiac pacing has been suggested as treatment of
recurrent syncope, and initial open label trials (comparing
pacing to medical therapy or no therapy) were encouraging
[7,8,11]. However, two truly blinded trials (pacing vs. sensing
only) could not demonstrate any effect of cardiac pacing on
syncope recurrence [6,9]. The recurrence rate for syncope in
patients with PM varies considerably (0e78%) depending on
mode of pacing [5e11]. Although pacing can address the
cardioinhibitory component of reflex syncope, the vasodila-
tation and hypotension associated with reflex syncope re-
mains unmanaged. In a recent trial, PM implantation was
guided by implantable loop recorders, selecting only patients
with spontaneous asystole. Using this approach pacing
reduced the syncope recurrence. However, 25% still experi-
enced syncope in the pacing arm of the study despite active
pacing [5]. The syncope mechanism in these patients with
pacemaker but recurrent syncope was not further described.implanted due to recurrent syncope and suspected sinus
d pressure tracing at time of syncope shows technical
ioventricular conduction (*) for 15 s leading to hypotension
cular conduction upon tilting down to horizontal position.
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likely, but other reasons should not be ruled out in advance,
and a HUT might be an appropriate way of acquiring both
clinical and patient-orientated reassurance.
Some patients with a negative HUT were paced continu-
ously throughout the procedure, with no significant change in
heart rate or blood pressure. As these patients were
completely dependent on their pacemaker, any cardioin-
hibitory or mixed response was not possible. However, this
could be due to the fact, that their HR had a very limited fre-
quency span e i.e., 50e80 bpm, thus, never qualifying for
cardioinhibitory or mixed response. Whether these patients
were “protected” from cardioinhibitory response or simply did
not have reflex syncope is thus speculative.
We could not demonstrate any difference in tilt table
outcome according to pacing mode, although all only atrial
paced patients had a positive outcome. Firstly, this could be
attributed to the highly selected population (patients with PM
and syncope referred to syncope unit), and secondly, to the
limited number of patients preventing any evident effect of
pacing mode. Multiple reports suggest differences between
pacing protocols and recurrence of syncope, with DDD pacing
being superior to DDI [19] and DDD-CLS pacing being superior
to DDI [10].
A number of studies have suggested value of performing
HUT in the evaluation of patients with PM and recurrent
syncope [15,17,18,20]. In the INVASY and VASIS studies [7,10],
HUT preformed after PM implantation in a fraction of patients
was not a predictor of clinical recurrence. In the paced group
in theVASIS study [7], five patients had a positive test without
pacemaker activation (HR remained above 45 bpm) and five
had positive tests despite pacemaker activation e similar to
our results. In patients with negative HUT and PM, the PM
was activated and possibly prevented syncope only in one
patient [7].
Thus, the value HUT for diagnosis of recurrent syncope in
PM patients seems well established. However the predictive
value of positive HUT after PM implantation is still not clear.
When comparing the outcome of our PM patients with a
large series of patients from our own syncope clinic, more
patients with PM required nitroglycerine provocation for a
positive result (90% vs. 68%) [13]. There was no difference in
the fraction of cardioinhibitory, mixed or vasodepressor
among positive responses and the diagnostic yield was
similar (54% in our series, 64% in the reference population).
The time to syncope in our study was marginally increased
compared to findings by others [13,21]. In the INVASY study,
the time to syncope/pre-syncope in 22 patients with pre-
syncope symptoms was increased from a mean of
14 mine20 min suggesting that CLS-pacing support pre-
vented asystole and prolonged the time to hypotensive
symptoms [10]. One can speculate that the pacemakers pro-
vided some sort of support, postponing the time to syncope
and thus, more patients requiring nitroglycerine. Whether
more patients experienced vasovagal response due to nitro-
glycerine or if the test was false positive is also speculative e
as mentioned compared to our other patients without pace-
makers we could not see an over reporting of vasovagal
outcomes and test was only considered positive if the
symptoms were similar to real life events.Limitations
The study included highly selected population from a single
center. Still the findings are in line with earlier reports from
patients with pacemakers. The diagnostic yield is also in line
with previous experience in our unit.
We have not conducted a full work up on patients, and can
therefore not definitely claim that their syncopewas related to
hypotensive responses. However, all pacemakers were nor-
mally functioning and tests were only declared positive if the
patient experienced symptoms during tilt test similar to their
real life events.
We did not study the effect of specific pacing mode or
advanced pacing algorithms due to limited number of patients
in each category. The literature suggests that closed-loop
stimulation pacing is superior to regular dual chamber pac-
ing algorithms in preventing vasovagal syncope.Conclusion
In PM patients referred for HUT due to recurrent syncope/pre-
syncope 54% had a positive result. Vasodepressor or ortho-
static hypotensive response was the most prevalent outcome
but mixed or cardioinhibitory responses were also seen e
adding diagnostic information that could help to optimize
either device or medical management. Pacing mode, pacing
indication and baseline data did not differ between patients
with and without positive HUT. The added value of HUT in
managing PM patients experiencing recurrent syncope seems
feasible with a high diagnostic yield and adding potentially
valuable clinical information about the patients' mode of
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